公开(公告)号：US20190284135A1

公开(公告)日：2019-09-19

申请号：US16421006

申请日：2019-05-23

Applicant: AbbVie Inc.

Inventor： Dominique Bonafoux ,  Heather Michele Davis ,  Kristine E. Frank ,  Michael M. Friedman ,  J. Martin Herold ,  Michael Z. Hoemann ,  Raymond Huntley ,  Augustine Osuma ,  George Sheppard ,  Gagandeep Kaur Somal ,  Jennifer Van Camp ,  Stacy Anne Van Epps ,  Anil Vasudevan ,  Grier Allan Wallace ,  Lu Wang ,  Lu Wang ,  Zhi Wang ,  Noel S. Wilson ,  Xiangdong Xu

IPC: C07D209/08 ,  C07D487/04 ,  C07D405/14 ,  C07D231/56 ,  C07D403/14 ,  C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D417/12 ,  A61P35/00 ,  C07D513/04 ,  C07D209/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D209/10 ,  C07D209/12 ,  C07D413/04 ,  C07D209/18 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D401/12

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

公开(公告)号：US10174061B2

公开(公告)日：2019-01-08

申请号：US15715245

申请日：2017-09-26

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Brian P. Enright ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao ,  Xiaochun Lou ,  Sean E. Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang ,  Valentino J. Stella

IPC: C07F9/09 ,  A61K31/661 ,  C07F9/06 ,  A61K31/6615 ,  C07C281/02 ,  C07C309/24 ,  C07C47/277 ,  A61K45/06

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

公开(公告)号：US20180079762A1

公开(公告)日：2018-03-22

申请号：US15715245

申请日：2017-09-26

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Kassibla Dempah ,  Brian P. Enright ,  Rodger F. Henry ,  Raimundo Ho ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao ,  Xiaochun Lou ,  Sean E. Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang ,  Valentino J. Stella

IPC: C07F9/09 ,  A61K31/661 ,  C07F9/06 ,  A61K45/06 ,  C07C47/277 ,  C07C309/24 ,  C07C281/02 ,  A61K31/6615

CPC classification number: C07F9/094 ,  A61K31/661 ,  A61K31/6615 ,  A61K45/06 ,  C07B2200/13 ,  C07C47/277 ,  C07C281/02 ,  C07C309/24 ,  C07F9/06 ,  A61K2300/00

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

公开(公告)号：US09446059B2

公开(公告)日：2016-09-20

申请号：US14919418

申请日：2015-10-21

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Kassibla E. Dempah ,  Brian P. Enright ,  Rodger F. Henry ,  Raimundo Ho ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao ,  Xiaochun Lou ,  Sean E. Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang ,  Valentino J. Stella

IPC: A61K31/661 ,  C07F9/06 ,  A61K31/6615

CPC classification number: C07F9/094 ,  A61K31/661 ,  A61K31/6615 ,  A61K45/06 ,  C07B2200/13 ,  C07C47/277 ,  C07C281/02 ,  C07C309/24 ,  C07F9/06 ,  A61K2300/00

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。